Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Other Working Capital Changes (2016 - 2026)

Lexaria Bioscience's Other Working Capital Changes history spans 12 years, with the latest figure at $8400.0 for Q1 2026.

  • Quarterly results put Other Working Capital Changes at $8400.0 for Q1 2026, down 98.84% from a year ago — trailing twelve months through Feb 2026 was $8400.0 (up 162.41% YoY), and the annual figure for FY2025 was $47001.0, up 847.22%.
  • Other Working Capital Changes for Q1 2026 was $8400.0 at Lexaria Bioscience, up from -$27556.0 in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $725275.0 in Q1 2025 to a low of -$743696.0 in Q4 2024.
  • The 5-year median for Other Working Capital Changes is -$13233.0 (2022), against an average of -$338.21.
  • The sharpest move saw Other Working Capital Changes plummeted 285.74% in 2022, then surged 3858.28% in 2023.
  • Year by year, Other Working Capital Changes stood at -$316419.0 in 2022, then surged by 96.46% to -$11204.0 in 2023, then tumbled by 6537.77% to -$743696.0 in 2024, then soared by 96.29% to -$27556.0 in 2025, then soared by 130.48% to $8400.0 in 2026.
  • According to Business Quant data, Other Working Capital Changes over the past three periods came in at $8400.0, -$27556.0, and -$9336.0 for Q1 2026, Q3 2025, and Q2 2025 respectively.